Isotope refinery, cold chain M&A and DARPA deals: pharma finance roundup

From a £10m isotope refinery raise to Copeland's Dickson acquisition and a $14m DARPA-backed red blood cell programme, here is this week's biggest pharma manufacturing and life sciences funding news

You need to be a subscriber to read this article.
Click here to find out more.

Isotope supply gets a manufacturing fix

UK deep tech company StandardX has raised £10m in seed funding, led by Vsquared Ventures and East X Ventures, to build what it calls the world's first scalable isotope refinery.Isotope refinery, cold chain M&A and DARPA deals: pharma finance roundup

The London-headquartered firm says its accelerator-based system can manufacture a full portfolio of isotopes at commercial scale from a standard industrial footprint — a direct response to a supply chain that is currently fragmented and reliant on ageing infrastructure.

For manufacturers, there is a real pinch point here: isotope shortages have already paused or delayed clinical trials for targeted alpha therapies across the UK and Europe.,

StandardX plans to supply its first isotopes to a medical research partner in 2027, with industrial-scale production targeted from 2029.

Longer term, the same platform is earmarked for tritium production to support fusion energy developers — a reminder that critical materials manufacturing is increasingly a cross-sector play.

Cold chain intelligence consolidates

Compression and controls giant Copeland has completed its acquisition of Dickson, a Chicago-based environmental monitoring and compliance technology provider serving regulated life sciences and healthcare environments.Isotope refinery, cold chain M&A and DARPA deals: pharma finance roundup

The deal combines Dickson's cloud-native monitoring platform with Copeland's controls and enterprise software, aimed at giving manufacturers continuous visibility from production through to patient delivery.

With regulatory scrutiny of temperature-sensitive product handling only increasing, this consolidation move is worth watching: it signals that investment is shifting toward end-to-end cold chain compliance rather than point-solution monitoring.

UK distribution changes hands

Duke Street has sold Kent Pharmaceuticals, a speciality and generic pharmaceuticals distributor and a top supplier of injectables to UK hospitals, to Phoenix Labs, expanding the Irish player's UK footprint.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like